Ovid Therapeutics (OVID) – Investment Analysts’ Weekly Ratings Updates

A number of firms have modified their ratings and price targets on shares of Ovid Therapeutics (NASDAQ: OVID) recently:

• 12/27/2025 – Ovid Therapeutics was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.
• 12/22/2025 – Ovid Therapeutics is now covered by analysts at Lifesci Capital. They set an “outperform” rating and a $4.00 price target on the stock.
• 12/22/2025 – Ovid Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $2.00 price target on the stock.
• 12/11/2025 – Ovid Therapeutics is now covered by analysts at Roth Capital. They set a “buy” rating and a $3.00 price target on the stock.
• 12/11/2025 – Ovid Therapeutics is now covered by analysts at Roth Capital. They set a “buy” rating and a $3.00 price target on the stock.
• 11/24/2025 – Ovid Therapeutics had its price target raised by analysts at HC Wainwright from $1.50 to $2.00. They now have a “buy” rating on the stock.
• 11/17/2025 – Ovid Therapeutics was upgraded by analysts at Leerink Partnrs to a “strong-buy” rating.
• 11/17/2025 – Ovid Therapeutics is now covered by analysts at Leerink Partners. They set an “outperform” rating and a $5.00 price target on the stock.
• 11/15/2025 – Ovid Therapeutics was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.

Ovid Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapies for rare neurological disorders. Founded in 2014 and headquartered in New York, the company applies a precision medicine approach to target underlying mechanisms of disease in patients with genetic conditions affecting the central nervous system. Its research platform centers on small-molecule modulators of neurotransmitter pathways to restore neural network function in disorders with high unmet medical need.

The company’s lead development candidate, OV101 (gaboxadol), is a selective extrasynaptic GABAA receptor agonist being investigated for the treatment of Angelman syndrome and Fragile X syndrome.